NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

Technology Appraisal No. 117; Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Manufacturers/sponsors	General
Amgen Ltd (Cinacalcet)	Allied Health Professionals Federation
	Board of Community Health Councils in
Patient/carer groups	Wales
Afiya Trust	 British National Formulary
Black Health Agency	 Care Quality Commission
British Kidney Patient Association	 Commissioning Support Appraisals
Equalities National Council	Service (CSAS)
Independent Age	 Department of Health, Social Services
Kidney Alliance	and Public Safety for Northern Ireland
Kidney Research UK	Healthcare Improvement Scotland
Muslim Council of Britain	Medicines and Healthcare Products
Muslim Health Network	Regulatory Agency
South Asian Health Foundation	National Association of Primary Care
Specialised Healthcare Alliance	National Pharmacy Association
	NHS Alliance
Professional groups	NHS Commercial Medicines Unit
Association of Anaesthetists of Great	NHS Confederation
Britain and Ireland	Public Health Wales NHS Trust
Association of Renal Industries	Scottish Medicines Consortium
Association of Renal Technologists	Welsh Kidney Patients Association
Association of Surgeons of GB and Isoland	Describle assuments and of stronger
Ireland	Possible comparator manufacturers
British Association for Services to the Eldorly (BASE)	AbbVie (Paricalcitol)
Elderly (BASE)British Association of Endocrine And	Relevant research groups
Thyroid Surgeons	Cochrane Metabolic and Endocrine
British Association of Urological	Disorders Group
Nurses	Cochrane Renal Group
British Geriatrics Society	Health Research Authority
British Renal Society	MRC Clinical Trials Unit
Renal Association	National Institute for Health Research
Royal College of Anaesthetists	Research Institute for the Care of Older

National Institute for Health and Care Excellence

Technology Appraisal No. 117; Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy Issue date: April 2013

Consultees	Commentators (no right to submit or
	appeal)
Royal College of General Practitioners	People
Royal College of Nursing	
 Royal College of Pathologists 	Assessment Group
Royal College of Physicians	Assessment Group tbc
Royal College of Surgeons	National Institute for Health Research
Royal Pharmaceutical Society	Health Technology Assessment
Royal Society of Medicine	Programme
 Society for Endocrinology Society of DGH Nephrologists The Urology Foundation UK Renal Pharmacy Group United Kingdom Clinical Pharmacy Association 	 Associated Guideline Groups National Clinical Guidelines Centre National Collaborating Centre for Acute and Chronic Conditions Associated Public Health Groups
Others	None
 Department of Health NHS Cumbria CCG NHS England NHS Redditch & Bromsgrove CCG Welsh Government 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence Technology Appraisal No. 117; Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy Issue date: April 2013

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment Group

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).